- Home
- BOWL vs AKRO Comparison
BOWL vs AKRO Comparison
Compare BOWL & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOWL
- AKRO
- Stock Information
- Founded
- BOWL 1900
- AKRO 2017
- Country
- BOWL United States
- AKRO United States
- Employees
- BOWL N/A
- AKRO N/A
- Industry
- BOWL Services-Misc. Amusement & Recreation
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- BOWL Consumer Discretionary
- AKRO Health Care
- Exchange
- BOWL Nasdaq
- AKRO Nasdaq
- Market Cap
- BOWL 1.6B
- AKRO 2.1B
- IPO Year
- BOWL N/A
- AKRO 2019
- Fundamental
- Price
- BOWL $10.82
- AKRO $31.59
- Analyst Decision
- BOWL Strong Buy
- AKRO Strong Buy
- Analyst Count
- BOWL 9
- AKRO 7
- Target Price
- BOWL $16.00
- AKRO $43.20
- AVG Volume (30 Days)
- BOWL 366.9K
- AKRO 441.5K
- Earning Date
- BOWL 11-04-2024
- AKRO 11-11-2024
- Dividend Yield
- BOWL 1.91%
- AKRO N/A
- EPS Growth
- BOWL N/A
- AKRO N/A
- EPS
- BOWL N/A
- AKRO N/A
- Revenue
- BOWL $1,154,614,000.00
- AKRO N/A
- Revenue This Year
- BOWL $9.73
- AKRO N/A
- Revenue Next Year
- BOWL $7.42
- AKRO N/A
- P/E Ratio
- BOWL N/A
- AKRO N/A
- Revenue Growth
- BOWL 9.05
- AKRO N/A
- 52 Week Low
- BOWL $8.85
- AKRO $11.36
- 52 Week High
- BOWL $15.47
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- BOWL 42.52
- AKRO 66.34
- Support Level
- BOWL $11.15
- AKRO $29.34
- Resistance Level
- BOWL $11.79
- AKRO $32.15
- Average True Range (ATR)
- BOWL 0.43
- AKRO 1.26
- MACD
- BOWL -0.09
- AKRO 0.10
- Stochastic Oscillator
- BOWL 3.99
- AKRO 99.74
About BOWL Bowlero Corp.
Bowlero Corp is a operator of bowling entertainment centers. It operate traditional bowling centers and more upscale entertainment concepts with lounge seating, arcades, enhanced food and beverage offerings, and more robust customer service for individuals and group events, as well as hosting and overseeing professional and non-professional bowling tournaments and related broadcasting.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.